XML 112 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid-In Capital
Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2023   169,867,414      
Beginning balance at Dec. 31, 2023 $ 106,018 $ 1,349,821 $ 81,270 $ (1,276,652) $ (48,421)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 2,014   2,014    
Issuance of common shares pursuant to the Open Market Sale Agreement (in shares)   8,666,077      
Issuance of common shares pursuant to the Open Market Sale Agreement 21,765 $ 21,765      
Issuance of common shares pursuant to exercise of options (in shares)   1,126,691      
Issuance of common shares pursuant to ESPP 2,454 $ 4,268 (1,814)    
Issuance of common shares pursuant to ESPP (in shares)   121,563      
Issuance of common shares pursuant to ESPP 211 $ 271 (60)    
Issuance of common shares upon vesting of RSUs   410,482      
Issuance of common shares upon vesting of RSUs 0 $ 1,190 (1,190)    
Unrealized gain on available-for-sale securities 50       50
Net loss (17,875)     (17,875)  
Ending balance (in shares) at Mar. 31, 2024   180,192,227      
Ending balance at Mar. 31, 2024 $ 114,637 $ 1,377,315 80,220 (1,294,527) (48,371)
Beginning balance (in shares) at Dec. 31, 2024 189,963,492 189,963,492      
Beginning balance at Dec. 31, 2024 $ 97,366 $ 1,410,025 82,048 (1,346,572) (48,135)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 3,564   3,564    
Issuance of common shares pursuant to exercise of options (in shares)   892,857      
Issuance of common shares pursuant to ESPP 2,653 $ 4,616 (1,963)    
Issuance of common shares pursuant to ESPP (in shares)   44,541      
Issuance of common shares pursuant to ESPP 131 $ 173 (42)    
Issuance of common shares upon vesting of RSUs   580,584      
Issuance of common shares upon vesting of RSUs 0 $ 1,518 (1,518)    
Unrealized gain on available-for-sale securities (31)       (31)
Net loss $ (24,526)     (24,526)  
Ending balance (in shares) at Mar. 31, 2025 191,481,474 191,481,474      
Ending balance at Mar. 31, 2025 $ 79,157 $ 1,416,332 $ 82,089 $ (1,371,098) $ (48,166)